Citigroup’s Direxion mRNA ETF MSGR Stock Holding History

Citigroup’s Portfolio MSGR Stock Details MSGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,700	Closed	-$196K	–	5887
2023 Q1	$196K	Sell	14,700 -7,964	-35%	-$116K	﹤0.01%	3749
2022 Q4	$323K	Sell	22,664 -1,236	-5%	-$17.3K	﹤0.01%	3465
2022 Q3	$324K	Sell	23,900 -1,100	-4%	-$16.5K	﹤0.01%	3522
2022 Q2	$338K	Hold	25,000	–	–	﹤0.01%	3524
2022 Q1	$444K	Hold	25,000	–	–	﹤0.01%	3596
2021 Q4	$594K	Buy	+25,000	New	+$601K	﹤0.01%	3668

Citigroup's MSGR Position: Q2 2023 in Review

Citigroup sold out of Direxion mRNA ETF (MSGR) in Q2 2023, closing a stake of 14,700 shares — an estimated $196K sold.

Citigroup first reported a position in MSGR in Q4 2021 and held it in 6 quarters. The position peaked at $594K in Q4 2021. 0 funds tracked by Wall St. Rank hold MSGR as of Q2 2023.

Citigroup reported no remaining Direxion mRNA ETF position as of Q2 2023 after selling out during the quarter.
Citigroup sold 14,700 Direxion mRNA ETF shares in Q2 2023, an estimated $196K.
Citigroup first reported a position in Direxion mRNA ETF in Q4 2021 and held it in 6 quarters.
Citigroup's Direxion mRNA ETF position peaked at $594K in Q4 2021.
0 funds tracked by Wall St. Rank held Direxion mRNA ETF as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.